ES2532948T3 - Composición tópica para el tratamiento de queratosis actínica - Google Patents

Composición tópica para el tratamiento de queratosis actínica Download PDF

Info

Publication number
ES2532948T3
ES2532948T3 ES09776876.6T ES09776876T ES2532948T3 ES 2532948 T3 ES2532948 T3 ES 2532948T3 ES 09776876 T ES09776876 T ES 09776876T ES 2532948 T3 ES2532948 T3 ES 2532948T3
Authority
ES
Spain
Prior art keywords
treatment
actinic keratosis
topical composition
alcohols
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09776876.6T
Other languages
English (en)
Inventor
Manfred Melzer
Carmen Matthies
Klaus Treudler
Christoph Willers
Henning Mallwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall Hermal GmbH
Original Assignee
Almirall Hermal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP08012237A priority Critical patent/EP2143421A1/en
Priority to EP08012237 priority
Application filed by Almirall Hermal GmbH filed Critical Almirall Hermal GmbH
Priority to PCT/EP2009/004682 priority patent/WO2010003568A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2532948(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application granted granted Critical
Publication of ES2532948T3 publication Critical patent/ES2532948T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una composición tópica en gel que comprende (a) del 0,25 al 4,5 % en peso de agente activo para el tratamiento de queratosis actínica seleccionado del grupo que consiste en inhibidores de ciclooxigenasa, inmunomoduladores tópicos, antimetabolitos y mezclas de los mismos, (b) un agente queratolíticamente activo, (c) un formador de gel y (d) un disolvente orgánico seleccionado del grupo que consiste en alcoholes C1-C10, ésteres de alcoholes C1-C10 con ácidos carboxílicos C1-C10, cetonas de alquilo C3-C8 y mezclas de los mismos y que comprende menos del 5 % en peso de agua para su uso en el tratamiento de queratosis actínica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
    imagen2
ES09776876.6T 2008-07-07 2009-06-29 Composición tópica para el tratamiento de queratosis actínica Active ES2532948T3 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis
EP08012237 2008-07-07
PCT/EP2009/004682 WO2010003568A1 (en) 2008-07-07 2009-06-29 Topical composition for the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
ES2532948T3 true ES2532948T3 (es) 2015-04-06

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09776876.6T Active ES2532948T3 (es) 2008-07-07 2009-06-29 Composición tópica para el tratamiento de queratosis actínica

Country Status (32)

Country Link
US (1) US8569320B2 (es)
EP (2) EP2143421A1 (es)
JP (2) JP5654987B2 (es)
KR (1) KR101689898B1 (es)
CN (2) CN102088957A (es)
AR (1) AR072685A1 (es)
AU (1) AU2009267471B2 (es)
BR (1) BRPI0915439B8 (es)
CA (1) CA2729974A1 (es)
CL (1) CL2010001642A1 (es)
CO (1) CO6351710A2 (es)
CY (1) CY1116111T1 (es)
DK (1) DK2315581T3 (es)
EA (1) EA019533B1 (es)
EC (1) ECSP11010762A (es)
ES (1) ES2532948T3 (es)
HK (1) HK1154793A1 (es)
HR (1) HRP20150222T1 (es)
IL (1) IL210134A (es)
ME (1) ME02147B (es)
MX (1) MX2011000054A (es)
MY (1) MY158428A (es)
NZ (1) NZ590288A (es)
PE (1) PE20110330A1 (es)
PL (1) PL2315581T3 (es)
PT (1) PT2315581E (es)
RS (1) RS53887B1 (es)
SI (1) SI2315581T1 (es)
TW (1) TWI433692B (es)
UA (1) UA101044C2 (es)
WO (1) WO2010003568A1 (es)
ZA (1) ZA201100653B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883767B2 (en) * 2009-10-08 2014-11-11 Msd Consumer Care, Inc. Low ether compositions and delivery apparatus
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
US20140322310A1 (en) * 2011-12-12 2014-10-30 Leo Laboratories Limited Gel compositions
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
MX2017001331A (es) * 2014-07-31 2017-05-23 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoina.
UA122145C2 (uk) 2015-07-10 2020-09-25 Інфектофарм Арцнейміттель Унд Консіліум Гмбх Застосування гідроксиду калію в лікуванні актинічного кератозу

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
BR9709920A (pt) * 1996-06-20 2000-01-11 Lavipharm Sa Dispositivo para tratamento tópico da acne e seu método de manufatura
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
BRPI0412975A (pt) * 2003-08-25 2006-10-03 Foamix Ltd espuma penetrante para uso farmacêutico
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
AU2005267396B2 (en) * 2004-06-24 2009-09-17 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
RS50693B (en) * 2005-06-14 2010-06-30 Uni-Pharma Kleon Tsetis Pharmaceutical Stable pharmaceutical gel of diclofenac sodium
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
AU2009267471B2 (en) 2014-06-05
JP2011526934A (ja) 2011-10-20
US20110301130A1 (en) 2011-12-08
UA101044C2 (ru) 2013-02-25
EA201100020A1 (ru) 2011-06-30
MX2011000054A (es) 2011-11-04
EA019533B1 (ru) 2014-04-30
PE20110330A1 (es) 2011-06-11
CO6351710A2 (es) 2011-12-20
ME02147B (me) 2015-10-20
PL2315581T3 (pl) 2015-06-30
US8569320B2 (en) 2013-10-29
CN104825384A (zh) 2015-08-12
IL210134A (en) 2015-06-30
ZA201100653B (en) 2011-10-26
EP2315581A1 (en) 2011-05-04
TWI433692B (zh) 2014-04-11
BRPI0915439B1 (pt) 2019-10-08
HK1154793A1 (en) 2012-05-04
AR072685A1 (es) 2010-09-15
WO2010003568A8 (en) 2011-02-03
TW201006507A (en) 2010-02-16
JP2015038129A (ja) 2015-02-26
BRPI0915439B8 (pt) 2021-05-25
IL210134D0 (en) 2011-02-28
WO2010003568A1 (en) 2010-01-14
CA2729974A1 (en) 2010-01-14
AU2009267471A1 (en) 2010-01-14
KR20110027838A (ko) 2011-03-16
RS53887B1 (en) 2015-08-31
SI2315581T1 (sl) 2015-05-29
PT2315581E (pt) 2015-04-02
ECSP11010762A (es) 2012-03-30
MY158428A (en) 2016-10-14
CY1116111T1 (el) 2017-02-08
EP2315581B1 (en) 2014-12-17
DK2315581T3 (en) 2015-03-23
CL2010001642A1 (es) 2011-04-08
JP5654987B2 (ja) 2015-01-14
KR101689898B1 (ko) 2016-12-26
EP2143421A1 (en) 2010-01-13
BRPI0915439A2 (pt) 2015-11-10
HRP20150222T1 (en) 2015-05-22
CN102088957A (zh) 2011-06-08
NZ590288A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
ES2575565T3 (es) Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2536206T3 (es) Parche medicinal
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
ES2575994T3 (es) Sistema y procedimiento para preparar, aplicar y retirar un revestimiento superior para gráficos despegables
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
AR097931A1 (es) Derivados de diazacarbazol como ligandos de tau para pet
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
PE20190914A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
EA201490178A1 (ru) Стабилизированные композиции для местного применения, содержащие микрокапсулы с ядром и оболочкой
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
ES2564521T3 (es) Métodos y composiciones para mejorar la entrada de aire en mezclas de cemento
ES2510403T3 (es) Composición antioxidante, sinérgica
ES2598753T3 (es) Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática